Herpival 1gm 3 Tablets

babies: it is not safe to use in < 12 years old individuals. lactating mothers: it is safe to use this medication in lactating mothers. studies suggest that it does not cause any harm to the baby. pregnancy: it is likely to be safe to use in pregnancy.
even though there are limited human studies, animal studies have shown no risk to the developing baby. driving: it is unsafe to use this medication while driving as it may affect your concentration. alcohol: studies are not available on the use of this medication while consuming alcohol.
seek your doctor's advice before using this medication. kidney: use this medication with caution in kidney disease patients. dose adjustment is necessary.
seek your doctor's advice. drink plenty of fluids. liver: it is safe to use this medication in liver disease patients.
dose adjustment is not necessary..

Headache Nausea Abdominal pain.

herpival tablet is a viral dna polymerase inhibitor class of medication. herpival tablet converts to acyclovir.
it works by stopping the multiplication of the virus by interfering with viral genetic material. thus it helps in decreasing the spread of infection to nearby cells..

If you miss a dose of herpival, take it as soon as possible. If it is near the time of the next dose, then skip the missed dose.
Take the prescribed dose on your regular time daily. Don't double the dose to catch up with the missed dose..

• herpival tablet is prescribed to treat viral infections like herpes labialis, genital herpes infection, and herpes zoster • do not discontinue this medication without informing your doctor as it may lead to a reversal and worsening of your condition • drink enough amounts of water while using this medication helps to prevent dehydration and damage to the kidneys • use effective contraceptive methods if you have genital herpes. if you have sores avoid sexual contact. • tell your physician if you are pregnant or intend to be pregnant or breastfeeding.

• fosphenytoin + valacyclovir: concurrent use of these medications may result in decreased phenytoin plasma concentrations and potential increased seizure activity • pethidine + valacyclovir: concurrent use of these medications may result in increased risk of cns stimulation and excitation • meperidine + valacyclovir: concurrent use of these medications may result in increased risk of cns stimulation and excitation • valproic acid + valacyclovir: concurrent use of these medications may result in decreased valproic acid plasma concentrations and potential increased seizure activity • divalproex sodium + valacyclovir: concurrent use of these medications may result in decreased valproic acid plasma concentrations and potential increased seizure activity • zidovudine + valacyclovir: concurrent use of these medications may result in increased lethargy and fatigue • teriflunomide + valacyclovir: concurrent use of these medications may result in increased exposure of oat3 substrate • leflunomide + valacyclovir: concurrent use of these medications may result in increased exposure of oat3 substrate • foscarnet + valacyclovir: concurrent use of these medications may result in increased risk of nephrotoxicity.